JLSWSRCZX2023-84)
Lewandowski SL, El K, Campbell JE

Individuals who should avoid or exercise extreme caution include: Immunocompromised patients : Those with primary immunodeficiency disorders, HIV/AIDS with low CD4 counts, active chemotherapy recipients, or individuals taking immunosuppressive medications (corticosteroids, biologics, transplant drugs) face increased infection risk Critically ill or hospitalized patients : Severely ill individuals, particularly those in intensive care settings or with compromised gut barrier function, should not receive probiotics outside controlled clinical protocols Patients with central venous catheters : Indwelling lines provide potential routes for bacterial translocation into the bloodstream Premature infants : The FDA issued a safety warning in October 2023 against using probiotics in preterm infants due to risk of invasive infection Patients with severe acute pancreatitis : Clinical guidelines from the American College of Gastroenterology recommend against probiotic use in this condition due to potential harm [15] [16] Additional populations requiring medical consultation: Pregnant and breastfeeding women should consult healthcare providers before using GLP-1 probiotics, as safety data in these populations remains limited

At 68 weeks, participants taking 2.4 mg of semaglutide (Wegovy) weekly lost 15.8% of their body weight, compared to 6.4% for participants taking 3 mg of liraglutide (Saxenda)
are NIHR clinical lecturers
The condition is reversible upon discontinuation of IGF-1 LR3